PT - JOURNAL ARTICLE AU - Negi, Shloka AU - Stenton, Sarah L. AU - Berger, Seth I. AU - McNulty, Brandy AU - Violich, Ivo AU - Gardner, Joshua AU - Hillaker, Todd AU - O’Rourke, Sara M AU - O’Leary, Melanie C. AU - Carbonell, Elizabeth AU - Austin-Tse, Christina AU - Lemire, Gabrielle AU - Serrano, Jillian AU - Mangilog, Brian AU - VanNoy, Grace AU - Kolmogorov, Mikhail AU - Vilain, Eric AU - O’Donnell-Luria, Anne AU - Délot, Emmanuèle AU - Miga, Karen H. AU - Monlong, Jean AU - Paten, Benedict TI - Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection AID - 10.1101/2024.08.22.24312327 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.22.24312327 4099 - http://medrxiv.org/content/early/2024/08/22/2024.08.22.24312327.short 4100 - http://medrxiv.org/content/early/2024/08/22/2024.08.22.24312327.full AB - More than 50% of families with suspected rare monogenic diseases remain unsolved after whole genome analysis by short read sequencing (SRS). Long-read sequencing (LRS) could help bridge this diagnostic gap by capturing variants inaccessible to SRS, facilitating long-range mapping and phasing, and providing haplotype-resolved methylation profiling. To evaluate LRS’s additional diagnostic yield, we sequenced a rare disease cohort of 98 samples, including 41 probands and some family members, using nanopore sequencing, achieving per sample ∼36x average coverage and 32 kilobase (kb) read N50 from a single flow cell. Our Napu pipeline generated assemblies, phased variants, and methylation calls. LRS covered, on average, coding exons in ∼280 genes and ∼5 known Mendelian disease genes that were not covered by SRS. In comparison to SRS, LRS detected additional rare, functionally annotated variants, including SVs and tandem repeats, and completely phased 87% of protein-coding genes. LRS detected additional de novo variants, and could be used to distinguish postzygotic mosaic variants from prezygotic de novos. Eleven probands were solved, with diverse underlying genetic causes including de novo and compound heterozygous variants, large-scale SVs, and epigenetic modifications. Our study demonstrates LRS’s potential to enhance diagnostic yield for rare monogenic diseases, implying utility in future clinical genomics workflows.Competing Interest StatementAnne ODonnell-Luria has consulted for Tome Biosciences, Ono Pharma USA Inc. and Addition Therapeutics and received research reagents from PacBio and Illumina.Funding StatementThe Chan Zuckerberg Initiative (CZI) provided funding for the sample collection, sequencing, and analyses.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of California, Santa Cruz waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors